Dr Reddy's Laboratories Ltd expected to post earnings of ₹17.90 a share - Earnings Preview

Reuters

05-07

Dr Reddy's Laboratories Ltd <rdy.n> expected to post earnings of ₹17.90 a share - Earnings Preview </rdy.n>

Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on May 9 for the period ending March 31 2025
The Hyderabad Telangana-based company is expected to report a 18.0% increase in revenue to ₹83.944 billion from ₹71.14 billion a year ago, according to the mean estimate from 17 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹17.90 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $15.76, above its last closing price of $13.51.

Previous quarterly performance (using preferred earnings measure in Indian rupees).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Dec. 31 2024	16.60	16.66	16.94	Beat	1.7
Sep. 30 2024	16.82	16.66	15.05	Missed	-9.7
Jun. 30 2024	15.90	15.62	16.69	Beat	6.9
Mar. 31 2024	15.30	13.68	15.67	Beat	14.6
Dec. 31 2023	15.51	14.09	16.56	Beat	17.6
Sep. 30 2023	14.10	13.92	17.78	Beat	27.8
Jun. 30 2023	11.36	11.44	16.87	Beat	47.5
Mar. 31 2023	10.53	10.50	11.52	Beat	9.5

This summary was machine generated May 7 at 11:15 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2533986833"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533986833\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2533986833?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533986833","market":"us","top_or_hot":-1,"title":"Dr Reddy's Laboratories Ltd  expected to post earnings of ₹17.90 a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Dr Reddy's Laboratories Ltd <rdy.n> expected to post earnings of ₹17.90 a share - Earnings Preview </rdy.n></title></head><body><ul><li><p>Dr Reddy's Laboratories Ltd <span>RDY.N</span>, <span>RDY</span> is expected to show a rise in quarterly revenue when it reports  results on May 9 for the period ending March 31 2025</p></li><li><p>The Hyderabad Telangana-based  company is expected to report a 18.0% increase in revenue to ₹83.944 billion from ₹71.14 billion a year ago, according to the mean estimate from 17 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹17.90 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $15.76, above its last closing price of $13.51. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in Indian rupees). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>16.60</p></td><td><p>16.66</p></td><td><p>16.94</p></td><td><p>Beat</p></td><td><p>1.7</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>16.82</p></td><td><p>16.66</p></td><td><p>15.05</p></td><td><p>Missed</p></td><td><p>-9.7</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>15.90</p></td><td><p>15.62</p></td><td><p>16.69</p></td><td><p>Beat</p></td><td><p>6.9</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>15.30</p></td><td><p>13.68</p></td><td><p>15.67</p></td><td><p>Beat</p></td><td><p>14.6</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>15.51</p></td><td><p>14.09</p></td><td><p>16.56</p></td><td><p>Beat</p></td><td><p>17.6</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>14.10</p></td><td><p>13.92</p></td><td><p>17.78</p></td><td><p>Beat</p></td><td><p>27.8</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>11.36</p></td><td><p>11.44</p></td><td><p>16.87</p></td><td><p>Beat</p></td><td><p>47.5</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>10.53</p></td><td><p>10.50</p></td><td><p>11.52</p></td><td><p>Beat</p></td><td><p>9.5</p></td></tr></tbody></table><p>This summary was machine generated May 7 at 11:15 GMT.  All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr Reddy's Laboratories Ltd  expected to post earnings of ₹17.90 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr Reddy's Laboratories Ltd  expected to post earnings of ₹17.90 a share - Earnings Preview\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-07 19:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Dr Reddy's Laboratories Ltd <rdy.n> expected to post earnings of ₹17.90 a share - Earnings Preview </rdy.n></title></head><body><ul><li><p>Dr Reddy's Laboratories Ltd <span>RDY.N</span>, <span>RDY</span> is expected to show a rise in quarterly revenue when it reports  results on May 9 for the period ending March 31 2025</p></li><li><p>The Hyderabad Telangana-based  company is expected to report a 18.0% increase in revenue to ₹83.944 billion from ₹71.14 billion a year ago, according to the mean estimate from 17 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹17.90 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $15.76, above its last closing price of $13.51. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in Indian rupees). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>16.60</p></td><td><p>16.66</p></td><td><p>16.94</p></td><td><p>Beat</p></td><td><p>1.7</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>16.82</p></td><td><p>16.66</p></td><td><p>15.05</p></td><td><p>Missed</p></td><td><p>-9.7</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>15.90</p></td><td><p>15.62</p></td><td><p>16.69</p></td><td><p>Beat</p></td><td><p>6.9</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>15.30</p></td><td><p>13.68</p></td><td><p>15.67</p></td><td><p>Beat</p></td><td><p>14.6</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>15.51</p></td><td><p>14.09</p></td><td><p>16.56</p></td><td><p>Beat</p></td><td><p>17.6</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>14.10</p></td><td><p>13.92</p></td><td><p>17.78</p></td><td><p>Beat</p></td><td><p>27.8</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>11.36</p></td><td><p>11.44</p></td><td><p>16.87</p></td><td><p>Beat</p></td><td><p>47.5</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>10.53</p></td><td><p>10.50</p></td><td><p>11.52</p></td><td><p>Beat</p></td><td><p>9.5</p></td></tr></tbody></table><p>This summary was machine generated May 7 at 11:15 GMT.  All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDY","symbol_name":"如瑞迪博士","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL8N3RF19Y:1","article_id":"2533986833","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533986833","pubTimestamp":1746616520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dr Reddy's Laboratories Ltd  expected to post earnings of 17.90 a share - Earnings Preview Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports  resul","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RDY":"如瑞迪博士"},"translate_title":"Dr Reddy's Laboratories Ltd预计将公布₹17.90 a股收益-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY":0.9},"content_text":"Dr Reddy's Laboratories Ltd  expected to post earnings of ₹17.90 a share - Earnings Preview Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports  results on May 9 for the period ending March 31 2025The Hyderabad Telangana-based  company is expected to report a 18.0% increase in revenue to ₹83.944 billion from ₹71.14 billion a year ago, according to the mean estimate from 17 analysts, based on LSEG data.LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹17.90 per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $15.76, above its last closing price of $13.51. Previous quarterly performance (using preferred earnings measure in Indian rupees). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Dec. 31 202416.6016.6616.94Beat1.7Sep. 30 202416.8216.6615.05Missed-9.7Jun. 30 202415.9015.6216.69Beat6.9Mar. 31 202415.3013.6815.67Beat14.6Dec. 31 202315.5114.0916.56Beat17.6Sep. 30 202314.1013.9217.78Beat27.8Jun. 30 202311.3611.4416.87Beat47.5Mar. 31 202310.5310.5011.52Beat9.5This summary was machine generated May 7 at 11:15 GMT.  All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}